Toward the end of January 2017, U.S. President Donald Trump held a meeting with executives from several big pharmaceutical companies and the head of PhRMA, the industry lobbying group. Trump pushed for lower drug prices in the U.S., and urged the companies to create more jobs in the U.S. For the most part, industry chief executives have kept their opinions to themselves, at least publicly. However, in interviews with Der Landbote and Bernet Zeitung newspapers, Joe Jimenez, chief executive officer of Novartis and head of PhRMA, responded to both key points.
U.S. Senate Republicans plan to unveil the text of their draft healthcare bill as senators struggle over issues such as the future of the Medicaid program for the poor and bringing down insurance costs.
Johnson & Johnson is seizing upon a U.S. Supreme Court ruling limiting where injury lawsuits can be filed to fight off claims it failed to warn women that talcum powder could cause ovarian cancer.
Coconut oil raises ‘bad’ cholesterol in the same way as other foods high in saturated fats like butter and beef, according to the American Heart Association.
Forecasts for global sales of pharmaceuticals have declined for the first time in a decade as continuing pressure on prices in the key U.S. market has caused analysts to moderate revenue expectations, according to a report.
The FDA approved Neos’ Cotempla XR-ODT, the first methylphenidate extended-release orally disintegrating tablet for treating ADHD in patients 6 to 17 years old.
Although a stock price does not always correlate to profitability, for bigger biopharma companies, profitability is a positive thing. Keith Speights, writing for The Motley Fool, takes a look at the five big pharma companies with the highest net margins in the industry.
Pamplona Capital Management, a private equity firm, is buying contract research organization Parexel International for a deal valued at about $5 billion.
Switzerland-based Novartis announced positive results from two Phase III trials, HAWK and HARRIER, of RTH258 in neovascular age-related macular degeneration (nAMD). In addition to being as effective as its nearest competitors, it requires fewer injections.
The U.S. Food and Drug Administration approved a new treatment for patients with acute bacterial skin infections, made by privately held Melinta Therapeutics.
There were 580 entries into this year’s Pharma category at Cannes Lions Health. That’s 580 case films accompanied by a slow, heart-wrenching solo piano track that begins with a few spare notes and builds to an optimistic outcome.
Scientists said they had pinpointed a particular type of immune system cell that could predict more precisely if cancer patients are likely to respond to modern immunotherapy medicines.
German-based life sciences giant Bayer AG is digging a deep foundation in the booming biotech hub of Boston.
Clovis Oncology announced topline results from a confirmatory Phase III ARIEL3 trial of Rubraca (ruparib) in platinum-sensitive ovarian cancer.
Seattle Genetics halted all clinical trials of its vadastuximab talirine due to higher incidents of death associated with the treatment for AML patients.
Publicis Health’s message delivery businesses announced that Brion Brandes has been named Executive Vice President of Business Development.
Switzerland’s Novartis increased pressure on Roche’s aging stable of big-selling drugs by becoming the latest company to win European approval for a cut-price version of Rituxan for blood cancer and immunological diseases.
PerkinElmer Inc. announced that it has entered into a definitive agreement to acquire EUROIMMUN Medical Laboratory Diagnostics AG. The agreement provides that PerkinElmer will acquire up to a 100% stake in EUROIMMUN.
Scientists have developed a new three-in-one blood test that has the potential to turn AstraZeneca’s drug Lynparza into a precision medicine for prostate cancer.